124I

You have access
¹²⁴I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma
Mariam S. Aboian, Shih-ying Huang, Miguel Hernandez-Pampaloni, Randall A. Hawkins, Henry F. VanBrocklin, Yoonsuk Huh, Kieuhoa T. Vo, W. Clay Gustafson, Katherine K. Matthay and Youngho Seo

Journal of Nuclear Medicine January 1, 2021, 62 (1) 43-47; DOI: https://doi.org/10.2967/jnumed.120.243139
You have access
Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors
Neeta Pandit-Taskar, Pat B. Zanzonico, Kim Kramer, Milan Grkovski, Edward K. Fung, Weiji Shi, Zhigang Zhang, Serge K. Lyashchenko, Alex M. Fung, Keith S. Pentlow, Jorge A. Carrasquillo, Jason S. Lewis, Steven M. Larson, Nai-Kong V. Cheung and John L. Humm

Journal of Nuclear Medicine December 1, 2019, 60 (12) 1794-1801; DOI: https://doi.org/10.2967/jnumed.118.219576
You have access
Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer
Francesco De Rose, Miriam Braeuer, Sten Braesch-Andersen, Angela M. Otto, Katja Steiger, Sybille Reder, Sabine Mall, Stephan Nekolla, Markus Schwaiger, Wolfgang A. Weber, Armando Bartolazzi and Calogero D’Alessandria

Journal of Nuclear Medicine June 1, 2019, 60 (6) 770-776; DOI: https://doi.org/10.2967/jnumed.118.219105
You have access
¹²⁴I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer
Walter Jentzen, Femke Verschure, Annelie van Zon, Rudie van de Kolk, Roel Wierts, Jochen Schmitz, Andreas Bockisch and Ina Binse

Journal of Nuclear Medicine October 1, 2016, 57 (10) 1499-1504; DOI: https://doi.org/10.2967/jnumed.115.170571
You have access
Assessment of Minimum ¹²⁴I Activity Required in Uptake Measurements Before Radioiodine Therapy for Benign Thyroid Diseases
Anja S. Gabler, Christian Kühnel, Thomas Winkens and Martin Freesmeyer

Journal of Nuclear Medicine August 1, 2016, 57 (8) 1201-1206; DOI: https://doi.org/10.2967/jnumed.115.171066
You have access
Dose–Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of ¹²⁴I PET/CT
Roel Wierts, Boudewijn Brans, Bas Havekes, Gerrit J. Kemerink, Servais G. Halders, Nicolaas N. Schaper, Walter H. Backes, Felix M. Mottaghy and Walter Jentzen

Journal of Nuclear Medicine July 1, 2016, 57 (7) 1027-1032; DOI: https://doi.org/10.2967/jnumed.115.168799
You have access
Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using ¹²⁴I
Walter Jentzen, Andreas Bockisch and Marcus Ruhlmann

Journal of Nuclear Medicine June 1, 2015, 56 (6) 832-838; DOI: https://doi.org/10.2967/jnumed.114.153031
You have access
Assessment of Lesion Response in the Initial Radioiodine Treatment of Differentiated Thyroid Cancer Using ¹²⁴I PET Imaging
Walter Jentzen, Jan Hoppenbrouwers, Paul van Leeuwen, Daan van der Velden, Rudie van de Kolk, Thorsten Dirk Poeppel, James Nagarajah, Wolfgang Brandau, Andreas Bockisch and Sandra Rosenbaum-Krumme

Journal of Nuclear Medicine November 1, 2014, 55 (11) 1759-1765; DOI: https://doi.org/10.2967/jnumed.114.144089
You have access
Quantitative ImmunoPET of Prostate Cancer Xenografts with ⁸⁹Zr- and ¹²⁴I-Labeled Anti-PSCA A11 Minibody
Scott M. Knowles, Kirstin A. Zettlitz, Richard Tavaré, Matthew M. Rochefort, Felix B. Salazar, David B. Stout, Paul J. Yazaki, Robert E. Reiter and Anna M. Wu

Journal of Nuclear Medicine March 1, 2014, 55 (3) 452-459; DOI: https://doi.org/10.2967/jnumed.113.120873
You have access
Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use
Brian D. Wright and Suzanne E. Lapi

Journal of Nuclear Medicine August 1, 2013, 54 (8) 1171-1174; DOI: https://doi.org/10.2967/jnumed.113.126086

Main menu

User menu

Search

124I